Jan 28, 2021 10:02 PM (GMT+8) · EqualOcean
Beida pharmaceutical announced that the net profit attributable to shareholders of Listed Companies in 2020 is expected to be 589 million yuan to 658 million yuan, a year-on-year increase of 155% to 185%. As icotinib has definite curative effect, low hepatotoxicity, high safety, abundant clinical evidence of evidence-based medicine and complete data of Chinese population, it has been recommended in CSCO guidelines, health care Commission diagnosis and treatment guidelines, brain metastasis population and 21-l858r NSCLC patients. It is also the only original EGFR-TKI drug that continues to carry out follow-up free drug use project at present, with obvious differentiation advantages. With the above differentiation advantages and years of word-of-mouth accumulation, icotinib sales continued to grow steadily. In addition, during the reporting period, the company's new drug, ALK inhibitor ensatinib, was approved to go on the market and generated sales revenue.